MedTrace Logo

SANCC: Clinical Trial Early Intervention

NCT03950037 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-04-12

No results posted yet for this study

Summary

Subarachnoid neurocysticercosis (SANCC) is a severe infection of the brain by the tapeworm Taenia solium. People who have this infection are usually diagnosed late in the disease process leading to very poor prognosis. This trial studies the safety of early medical intervention in people who have SANCC but do not have symptoms. The trial will enroll 18 participants in Peru.

Conditions

  • Subarachnoid Neurocysticercosis

Interventions

DRUG

Albendazole

Albendazole; 15 mg/k/d divided in two doses (morning and evening), for 30 days, with a ceiling in 1200 mg/d.

Sponsors & Collaborators

  • Universidad Peruana Cayetano Heredia

    collaborator OTHER

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • Seth E O'Neal, MD MPH · Oregon Health and Science University

  • Hector H Garcia, MD PhD · Universidad Peruana Cayetano Heredia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2023-04-30
Completion
2023-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03950037 on ClinicalTrials.gov